基于血流动力学监测的液体平衡中和策略与方案化标准治疗在需持续肾脏替代治疗的危重患者中的比较:GO NEUTRAL随机对照试验研究方案
GO NEUTRAL是多中心、开放标签、随机对照优效性试验,1:1平行分组,纳入使用血管加压药且有严重急性肾损伤需CRRT的成人急性循环衰竭患者。对照组在入组至入组后72小时接受方案化液体清除,净超滤率设为0-25 ml/h;干预组在血流动力学耐受前提下,净超滤率至少100 ml/h,依据心输出量、动脉乳酸和前负荷依赖性调整。主要结局为入组至入组后72小时的累积液体平衡。
要点
- GO NEUTRAL为多中心、开放标签、随机对照优效性试验,1:1平行分组。
- 对照组净超滤率设为0-25 ml/h,干预组在血流动力学耐受下至少100 ml/h。
- 主要结局为入组至入组后72小时的累积液体平衡。
核心结论
- 研究方案旨在通过先进血流动力学监测保障净超滤的实施,以实现液体平衡控制并预防液体过负荷。
研究设计与样本
- 多中心、开放标签、随机对照优效性试验,平行分组,1:1平衡随机化。
- 纳入使用血管加压药且需CRRT的成人急性循环衰竭患者,已配备连续心输出量监测装置。
- 随机化采用随机区组大小,并按入组时液体过负荷状态分层。
- 主要结局在改良意向治疗人群中分析,即入组后72小时仍存活的患者,按其初始分配组分析。
主要发现
- 约50%接受CRRT的ICU患者血流动力学不稳定事件与前负荷依赖性无关。
关键数值与推荐
- 对照组:入组至入组后72小时净超滤率设为0-25 ml/h。
- 干预组:入组至入组后72小时净超滤率至少100 ml/h,需基于方案化血流动力学方案评估耐受。
- 血流动力学方案依据心输出量、动脉乳酸浓度及体位动作评估的前负荷依赖性调整净超滤。
- 主要结局为入组至入组后72小时的累积液体平衡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluid overload is associated with worse outcome in critically ill patients requiring continuous renal replacement therapy (CRRT). Net ultrafiltration (UFNET) allows precise control of the fluid removal but is frequently ceased due to hemodynamic instability episodes. However, approximately 50% of the hemodynamic instability episodes in ICU patients treated with CRRT are not associated with preload dependence (i.e., are not related to a decrease in cardiac preload), suggesting that volume removal is not responsible for these episodes of hemodynamic impairment. The use of advanced hemodynamic monitoring, comprising continuous cardiac output monitoring to repeatedly assess preload dependency, could allow securing UFNET to allow fluid balance control and prevent fluid overload. METHODS: The GO NEUTRAL trial is a multicenter, open-labeled, randomized, controlled, superiority trial with parallel groups and balanced randomization with a 1:1 ratio. The trial will enroll adult patients with acute circulatory failure treated with vasopressors and severe acute kidney injury requiring CRRT who already have been equipped with a continuous cardiac output monitoring device. After informed consent, patients will be randomized into two groups. The control group will receive protocolized fluid removal with an UFNET rate set to 0-25 ml h-1 between inclusion and H72 of inclusion. The intervention group will be treated with an UFNET rate set on the CRRT of at least 100 ml h-1 between inclusion and H72 of inclusion if hemodynamically tolerated based on a protocolized hemodynamic protocol aiming to adjust UFNET based on cardiac output, arterial lactate concentration, and preload dependence assessment by postural maneuvers, performed regularly during nursing rounds, and in case of a hemodynamic instability episode. The primary outcome of the study will be the cumulative fluid balance between inclusion and H72 of inclusion. Randomization will be generated using random block sizes and stratified based on fluid overload status at inclusion. The main outcome will be analyzed in the modified intention-to-treat population, defined as all alive patients at H72 of inclusion, based on their initial allocation group. DISCUSSION: We present in the present protocol all study procedures in regard to the achievement of the GO NEUTRAL trial, to prevent biased analysis of trial outcomes and improve the transparency of the trial result report. Enrollment of patients in the GO NEUTRAL trial has started on June 31, 2021, and is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov NCT04801784. Registered on March 12, 2021, before the start of inclusion.
引用
- Bitker L, Pradat P, Dupuis C, et al. Fluid balance neutralization secured by hemodynamic monitoring versus protocolized standard of care in critically ill patients requiring continuous renal replacement therapy: study protocol of the GO NEUTRAL randomized controlled trial. Trials. 2022. PMID: 36138465. doi:10.1186/s13063-022-06735-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。